Physician profile
William C Freeman
NPI 1164462826
$4,222.51
in general payments reported to CMS, 2019-2025
23 companies · $220 in 2025
The $220 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $984 · 2020: $1,430 · 2021: $1,239 · 2023: $52.10 · 2024: $296 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $568.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $572.57 | 2019-2025 | Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $563.65 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $469.68 | 2019-2025 | Abilify Maintena |
| Allergan, INC. | $435.86 | 2019-2020 | |
| Abbvie INC. | $299.66 | 2021 | |
| Sunovion Pharmaceuticals INC. | $242.10 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $200.67 | 2019-2024 | Ingrezza |
| Alkermes, INC. | $190.18 | 2020-2023 | Aristada, Lybalvi |
| Bausch Health US, LLC | $176.06 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $168.15 | 2020-2025 | Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $146.81 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $142.20 | 2019-2021 | |
| Eisai INC. | $112.14 | 2020-2021 | |
| Adlon Therapeutics L.P. | $88.48 | 2020-2021 | |
| Shire North American Group INC | $87.84 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $87.32 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $61.25 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $56.92 | 2019 | |
| Neuronetics, INC. | $38.79 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $23.91 | 2021 | |
| Jazz Pharmaceuticals INC. | $22.94 | 2019 | |
| Merck Sharp & Dohme LLC | $22.65 | 2019 | |
| Amgen INC. | $12.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.